Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients

Michael Mahler, E. L. Greidinger, M. Szmyrka, A. Kromminga, M. J. Fritzler

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Scopus citations

Abstract

Antibodies to double-stranded desoxyribonucleic acid (ds-DNA) and to the polymyositis/scleroderma (PM/Scl) complex are regarded as serological markers for systemic lupus erythematosus (SLE) and PM/Scl overlap syndrome, respectively. In a previous study, serum samples were identified that contained antibodies specific for both ds-DNA and PM/Scl. Fourteen of these sera were available for more detailed investigation including the autoantibody profile as determined by several methods including an addressable laser bead assay, Crithidia luciliae indirect immunofluorescence test (CLIFT) and a PM1-Alpha ELISA. Moreover, 300 samples from connective tissue disease patients and 30 PM/Scl positive samples were screened for anti-dsDNA+/PM/Scl + specimens by CLIFT, dsDNA ELISA, and PM1-Alpha ELISA. We confirmed anti-dsDNA and anti-PM/Scl reactivity in 2/7 samples from the previous study. One sample had also anti-chromatin and anti-SS-A reactivity and the second sample was oligoreactive. In addition, 2/300 (0.7%) unselected samples from connective tissue disease patients were identified with anti-dsDNA and anti-PM/Scl reactivity. In a panel of PM1-Alpha positive samples (n = 30) collected regardless of the diagnosis of the patients, no anti-dsDNA reactivity was found. All anti-dsDNA+/anti-PM/Scl+ patients identified fulfilled sufficient criteria to be classified as definite SLE and also had at least one feature of systemic sclerosis (i.e., sclerodactyly and/or Raynaud's phenomenon). Only 1/4 patients had clinical evidence of dermatomyositis. The combination of anti-dsDNA+/anti-PM/Scl + in patients suffering from connective tissue disease is less frequently found than previously described when newer assays are used. Clinically, anti-dsDNA+/anti-PM/Scl+ patients may define a small subgroup of SLE patients with additional features of systemic sclerosis.

Original languageEnglish (US)
Title of host publicationAutoimmunity, Part A Basic Principles and New Diagnostic Tools
PublisherBlackwell Publishing Inc.
Pages311-321
Number of pages11
ISBN (Print)1573316636, 9781573316637
DOIs
StatePublished - Aug 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1109
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Keywords

  • Autoantibody
  • dsDNA
  • Peptide
  • PM/Scl
  • SLE

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients'. Together they form a unique fingerprint.

  • Cite this

    Mahler, M., Greidinger, E. L., Szmyrka, M., Kromminga, A., & Fritzler, M. J. (2007). Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients. In Autoimmunity, Part A Basic Principles and New Diagnostic Tools (pp. 311-321). (Annals of the New York Academy of Sciences; Vol. 1109). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1398.037